Cancer has become one of the leading causes of disease-related death globally. According to updated global cancer statistics from the International Agency for Research on Cancer (IARC), there were nearly 20 millionRead More…
Today, when talking about cancer color change, pancreatic cancer can be said to be a “tough role” in cancer. It is highly malignant and ranks seventh in the world. Among them, pancreaticRead More…
Among all emerging technologies for cancer therapy, one is both highly accurate and efficient: Antibody-Drug Conjugates (ADCs). These missiles are the first such missiles that allow us to kill cancer cells while doingRead More…
The newer cancer treatment is an antibody-drug conjugate (ADC) that combines the immunoprecision of monoclonal antibodies with the cytotoxicity of chemotherapy. It’s a two-step mechanism to ensure therapeutic molecules get to the cancerRead More…
The highly anticipated 115th American Association for Cancer Research (AACR 2024) Annual Meeting opened in San Diego, USA. As the focus of the cancer research community, scientists, clinicians, and cancer researchers fromRead More…
Bayer and Bicycle Therapeutics announced a strategic partnership agreement to develop, manufacture and commercialize targeted radiation conjugate drugs in the field of oncology using Bicycle Therapeutics’s synthetic peptide technology. Targeted radiotherapy isRead More…
Recently, FDA has accelerated the approval of ADC Therapeutics’ targeted CD19-ADC drug Loncastuximab tesirine for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). It is worth mentioning that,Read More…
Protein drugs have high risks of inducing immunogenicity, which may affect the efficacy or even be life-threatening. Most biotherapies, such as antibody-drug conjugates (ADCs), fusion proteins, and polyethylene glycolization, carry unnatural humanRead More…
On September 13, 2020, Gilead announced that it would acquire Immunomedics, whose core product is Trop-2 ADC drug Trodelvy, for more than $20 billion. On September 14, 2020, Merck Sharp & DohmeRead More…
On Sept. 12, the Wall Street Journal reported that Gilead was reaching an acquisition agreement of more than $20 billion with Immunomedics to expand its oncology product pipeline, including trodelvy (sacituzumab govitecan),Read More…